Nevakar Inc.
  • Home
  • comp001
    • comp001b
  • comp002
  • Nevakar
  • NevakarInjectables
  • Vyluma
Select Page

Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance

by @dministrator | Mar 9, 2022 | Vyluma

Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....

VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS

by @dministrator | Oct 7, 2021 | Vyluma

Bridgewater, NJ (October 7, 2021) – Vyluma Inc. and MyMyopiaTM (MyMyopia.com) are excited to announce new tools and resources to support the International Agency for the Prevention of Blindness (IAPB) World Sight Day, a global event to draw attention to blindness and...

VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

by @dministrator | May 25, 2021 | Vyluma

Bridgewater, NJ (May 25, 2021) – Vyluma Inc. announces its establishment as a wholly owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The robust pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eyedrop to slow...

NEVAKAR AND THÉA ENTER INTO LICENSING AGREEMENT FOR THE COMMERCIALIZATION OF NVK002 (ATROPINE FOR THE TREATMENT OF THE PROGRESSION OF MYOPIA IN CHILDREN) IN EUROPE

by @dministrator | Jan 28, 2021 | Vyluma

Bridgewater, NJ, USA and Clermont-Ferrand, France, January 28, 2021 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered...

Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK002 for the Treatment of Myopia in Children

by @dministrator | Jan 28, 2021 | Vyluma

Bridgewater, NJ, USA and Clermont-Ferrand, France, January 28, 2021 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered...

American Academy of ophthalmology leads global initiative to address worldwide myopia epidemic

by @dministrator | Nov 11, 2020 | Vyluma

SAN FRANCISCO – Nov. 11, 2020 – The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia,...
« Older Entries

Recent Posts

  • Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
  • Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
  • Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
  • VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS
  • VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

Recent Comments

    Archives

    • March 2022
    • October 2021
    • May 2021
    • March 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • May 2020
    • November 2019
    • October 2019
    • September 2019
    • June 2019
    • August 2018
    • November 2017
    • June 2017
    • July 2016
    • June 2015

    Categories

    • NevakarInjectables
    • Vyluma

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress